NEW Zealand's Medsafe regulator has issued a "monitoring communication" about the possible risk of lichen planus or lichenoid drug eruption in relation to the use of zoster (shingles) or influenza vaccine.
The potential safety signal was triggered by a report received by the Centre for Adverse Reactions Monitoring, in relation to a 67-year-old female patient who experienced a lichen planus rash after receiving both zoster vaccine and influenza vaccine.
The patient was also on other medications including quinapril + hydrochlorothiazide, which has been associated with lichenoid eruptions, Medsafe said.
The early warning alert aims to encourage further reports and increase the information on the potential adverse reaction - for more information on the issue see medsafe.govt.nz.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Nov 18
